Their data revealed that the combination of bortezomib (a proteasome inhibitor) with TSA or SAHA (HDAC inhibitors) demonstrated synergistic cytotoxicity in HPV-positive cervical cancer cell lines, while it had no such effect on HPV cell lines-negative. The gene discussed is HDAC9; the disease is cervical carcinoma.